Compare Incyte Corporation (INCY) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Strategy Inc. — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Strategy Inc. trades at $97.73 (market cap $37.84B). The key difference: Strategy Inc. is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals.
| INCY | MSTR | |
|---|---|---|
Market Cap | $24.54B | $37.84B |
Sector | Health | Technology |
52-Week High | $129.93 | $394.39 |
52-Week Low | $81.61 | $82.31 |
Enterprise Value | $20.04B | $56.61B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
